Adalimumab in acute sciatica reduces the long-term need for surgery: A 3-year follow-up of a randomised double-blind placebo-controlled trial

Annals of the Rheumatic Diseases

Volumn 71, Issue 4, 2012, Pages 560-562

  Genevay, Stephane ^a   Finckh, A ^a   Zufferey, P ^b   Viatte, S ^c   Balague F ^d   Gabay, C ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d Hopital Cantonal de Fribourg   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTAGONIST; UNCLASSIFIED DRUG;

ABSENTEEISM; ADULT; ARTICLE; BACKACHE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; INTERVERTEBRAL DISKECTOMY; ISCHIALGIA; LEG PAIN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SHORT COURSE THERAPY; SYMPTOM; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BACK PAIN; DISKECTOMY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SCIATICA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857915847     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200373     Document Type: Article

References (12)

1. Fairbank JC. Sciatic: An archaic term. BMJ 2007;335:112.
2. Genevay S, Atlas SJ, Katz JN. Variation in eligibility criteria from studies of radiculopathy due to a herniated disc and of neurogenic claudication due to lumbar spinal stenosis: a structured literature review. Spine 2010;35:803-11.
3. Valat JP, Genevay S, Marty M, et al. Sciatica. Best Pract Res Clin Rheumatol 2010;24:241-52.
4. Genevay S, Finckh A, Payer M, et al. Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated disc. Spine 2008;33:2041-6.
5. Genevay S, Viatte S, Finckh A, et al. Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:2339-46.
6. Vogler D, Paillex R, Norberg M, et al. Cross-cultural validation of the Oswestry disability index in French. Ann Readapt Med Phys 2008;51:379-85.
7. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33. (Pubitemid 126433231)
8. Leung L, Cahill CM. TNF-alpha and neuropathic pain-a review. J Neuroinflammation 2010;7:27.
9. Korhonen T, Karppinen J, Malmivaara A, et al. Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up. Spine 2004;29:2115-19. (Pubitemid 40353199)
10. Cohen SP, Bogduk N, Dragovich A, et al. Randomized, double-blind, placebocontrolled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology 2009;110:1116-26.
11. Okoro T, Tafazal SI, Longworth S, et al. Tumor necrosis alpha-blocking agent (etanercept): a triple blind randomized controlled trial of its use in treatment of sciatica. J Spinal Disord Tech 2010;23:74-7.
12. Korhonen T, Karppinen J, Paimela L, et al. The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial. Spine 2006;31:2759-66. (Pubitemid 44772773)